Please login to the form below

Not currently logged in
Email:
Password:

Warner Chilcott buy P&G's pharma business

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products.

The porfolio of products involved in the acquisition includes Asacol HD (mesalamine), Actone (risedronate sodium) and the co-promotion rights to Enablex (darifenacin), as well as Proctor & Gamble's (P&G) prescription drug product pipeline and manufacturing facilities in Puerto Rico and Germany. Of the 2,300 employees at P&G's pharmaceuticals business, the majority are expected to transfer to Warner Chilcott.

The transaction – for $3.1bn – is likely to close by the end of 2009, pending necessary regulatory approvals. 

Said Roger Boissonneault, president and chief executive officer of Warner Chilcott: "The acquisition transforms Warner Childcott into a global pharmaceutical company, expands our presence in women's healthcare, establishes us in the urology market in advance of the anticipated launch of our erectile dysfunction treatments, and adds gastroenterology therapies to our product portfolio."

P&G said that it believes Warner Chilcott will be a strong investor in P&G's pharmaceutical assets, brands and capabilities and that the move will enable them to "focus singularly on winning in consumer health care".

24th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics